Proactively evaluate Lupin Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
|Event Date||Event Type||Company Name||Ticker Symbol||Drug Name||Therapy Area||Indication||Source Type|
|01 Mar 2020||GDCTXXXX||Lorem||Lorem||Lorem||XXXX||Planned||Lorem|
|31 Dec 2019||NDA/BLA Filing (US)||Lupin Ltd||LUPIN||etanercept biosimilar||Immunology||Rheumatoid Arthritis||Company Website|
|31 Dec 2019||NDA/BLA Filing (US)||Lupin Ltd||LUPIN||filgrastim||Toxicology||Chemotherapy Induced Neutropenia||Company Website|
|31 Dec 2019||NDA/BLA Filing (US)||Lupin Ltd||LUPIN||pegfilgrastim||Hematological Disorders; Toxicology||Chemotherapy Induced Neutropenia; Febrile Neutropenia||Company Website|
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer